Diagnosis of iron deficiency in patients undergoing hemodialysis

American Journal of Clinical Pathology

Volumn 133, Issue 6, 2010, Pages 949-954

  Buttarello, Mauro ^a,c   Pajola, Rachele ^a   Novello, Enrica ^a   Rebeschini, Mirca ^a   Cantaro, Salvatore ^a   Oliosi, Fausto ^a   Naso, Agostino ^a   Plebani, Mario ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Leonardo Foundation   (Italy)

^c Azienda ULLS 19 ^*  (Italy)

Author keywords

ADVIA 120; Hemodialysis; Hypochromic erythrocytes; Iron deficiency; Reticulocyte hemoglobin content; XE 5000

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ARTICLE; ERYTHROCYTE; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; PARAMETER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETICULOCYTE HEMOGLOBIN CONTENT; SENSITIVITY AND SPECIFICITY; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; IRON DEFICIENCY ANEMIA; PREDICTION AND FORECASTING; RENAL REPLACEMENT THERAPY; RETICULOCYTE;

ANEMIA, IRON-DEFICIENCY; ERYTHROCYTES; FERRITINS; HEMOGLOBINS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RETICULOCYTES; TRANSFERRIN;

EID: 77952989605     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPQAX0JFHFS0OA     Document Type: Article

References (29)

1. Braumann KM, Nonnast-Daniel B, Boning D, et al. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron. 1991;58:129-134.
2. Robertson HT, Haley NR, Guthrie M, et al. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis. 1990;15:325-332. (Pubitemid 20257471)
3. Wolcott DL, Marsh JT, La Rue A, et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis. 1989;14:478-485.
4. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia in cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
5. Evans RW, Rader B, Manninen DL, and the Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA. 1990;263:825-830.
6. Delano BG. Improvement in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989;14:14-18.
7. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity: the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13:1642-1644.
8. Locatelli F, Aljama P, Barany P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):ii1-ii47.
9. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease [published correction appears in Am J Kidney Dis. 2006;48:518]. Am J Kidney Dis. 2006;47(suppl 3):S11-S145.
10. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530. (Pubitemid 47285453)
11. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis. 1997;29:319-333. (Pubitemid 27106553)
12. Taylor JE, Peat N, Porter C, et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patient. Nephrol Dial Transplant. 1996;14:1079-1083. (Pubitemid 26182502)
13. Coyne D. Challenging the boundaries of anemia management: a balanced approach to i.v. iron and EPO therapy. Kidney Int Suppl. 2006;69:S1-S3.
14. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16:1416-1423.
15. Bovy C, Gothot A, Delanaye P, et al. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant. 2007;22:1156-1162. (Pubitemid 46523432)
16. Tycko DH, Metz MH, Epstein EA, et al. Flow-cytometric light scattering measurement of red blood cell volume and hemoglobin concentration. Appl Opt. 1985;24:1355-1365.
17. Buttarello M, Temporin V, Ceravolo R, et al. The new reticulocyte parameter (RET-Y) of the Sysmex XE-2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia. Am J Clin Pathol. 2004;121:489-495. (Pubitemid 38392956)
18. Franck S, Linssen J, Messinger M, et al. Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis. Clin Chem. 2004;50:1240-1242.
19. Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001;60:2406-2411.
20. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol. 2002;57:136-141.
21. Singh AK, Coyne DW, Shapiro W, et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007;71:1163-1171.
22. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte haemoglobin content predicts functional iron deficiency in hemodialysis patient receiving rHuEPO. Am J Kidney Dis. 1997;30:912-922.
23. Fishbane S, Kowalsky EA, Imbriano LJ, et al. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol. 1996;7:2654-2657. (Pubitemid 27469573)
24. Lin JL, Chang MY, Tan DT, et al. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol. 2001;21:91-97.
25. Kaneko J, Miyazaki S, Hirasawa Y, et al. Transferrin saturation versus reticulocyte haemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int. 2003;63:1086-1093.
26. Mitsuiki K, Harada A, Miyata Y. Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte haemoglobin content. Clin Exp Nephrol. 2003;7:52-57.
27. Kim JM, Ihm CH, Kim HJ. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients. Int J Lab Hematol. 2008;30:46-52.
28. The Renal Association. Clinical Practice Guidelines Module 2: complications. 2007. http://www.renal.org/Clinical/ GuidelinesSection/ ComplicationsofCKD.aspx#full-S3. Accessed December 14, 2008.
29. Chuang CL, Liu RS, Wei YH, et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant. 2003;18:370-377.